Swedish Orphan Biovitrum AB / Apellis Pharmaceuticals, Inc.

Paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases (ex-US)

2K US cases/yr · $5.5B Global PNH and complement-mediated disease drug market 2020 (USD MM) · 40 % PNH patients with suboptimal response to C5 inhibition (PEGASUS trial enrollment criterion)

Disease Overview

Paroxysmal nocturnal hemoglobinuria is an ultra-rare acquired hematologic disorder caused by somatic PIGA mutations in hematopoietic stem cells, leading to absent GPI-anchored complement regulators CD55 and CD59 on red blood cells, granulocytes, and platelets. The result is chronic complement-mediated intravascular hemolysis, thromboembolism (the leading cause of mortality), bone marrow failure, and chronic kidney disease. PNH affects approximately 1-1.5 per million population, translating to roughly 5,000-10,000 prevalent US patients (similar prevalence ex-US in EU5 markets — combined ~10,000-15,000 prevalent in EU5). Prior to complement inhibitor therapy, median survival was approximately 10 years; thrombosis accounted for 40-67% of deaths. Soliris (eculizumab, Alexion — anti-C5 mAb), launched in 2007, was the first transformative therapy and is the standard of care for hemolytic PNH globally; it generated $4.06B in worldwide revenue in 2019. Ultomiris (ravulizumab, Alexion — long-acting anti-C5) launched 2018-2019 with 8-week dosing vs Soliris 2-week dosing. Roughly 30-40% of Soliris-treated patients have suboptimal response with persistent extravascular hemolysis driven by C3 fragment opsonization — the rationale for Apellis's pegcetacoplan (proximal C3 inhibitor). Pegcetacoplan demonstrated superior hemoglobin improvement vs Soliris in the PEGASUS Phase 3 (NEJM 2021), supporting FDA approval as Empaveli May 14, 2021 — six months after the Sobi deal.

Competitive Landscape

At deal date (Oct 2020), the PNH and complement-mediated disease landscape was dominated by Alexion's anti-C5 monopoly. Soliris (eculizumab, Alexion — first PNH approval 2007, $4.06B 2020 revenue) and Ultomiris (ravulizumab, Alexion — approved 2018, $1.08B 2020 revenue, transitioning Soliris patients) controlled the C5 PNH and aHUS markets. Pegcetacoplan (Apellis — pegylated cyclic peptide C3 inhibitor) was the only late-stage proximal complement inhibitor with PEGASUS Phase 3 readout positive in August 2020 (16-week hemoglobin improvement +2.4 g/dL vs -1.5 g/dL for eculizumab). The broader pipeline included: iptacopan (LNP023, Novartis — oral factor B inhibitor, Phase 3 APPLY-PNH, later approved as Fabhalta Dec 2023), danicopan (ALXN2040/ACH-4471, Achillion/Alexion — oral factor D inhibitor, approved Voydeya Mar 2024 as add-on), crovalimab (Roche/Chugai — anti-C5 with sweeping antibody design, Phase 3 COMMODORE), cemdisiran (Alnylam/Regeneron — C5 siRNA, Phase 2), zilucoplan (Ra Pharma/UCB — anti-C5 macrocyclic peptide, withdrew PNH program for myasthenia gravis), and POT-4 / APL-1030 (Apellis ophthalmology). Adjacent indications targeted with complement inhibitors include atypical hemolytic uremic syndrome (Soliris, Ultomiris, iptacopan), C3 glomerulopathy (pegcetacoplan, iptacopan), cold agglutinin disease (Sutimlimab/Enjaymo, Sanofi — approved Feb 2022, originated from Bioverativ acquired by Sanofi 2018), generalized myasthenia gravis (Soliris, Ultomiris, Vyvgart/efgartigimod — Argenx FcRn), and IgA nephropathy (iptacopan). The Sobi-Apellis deal handed Sobi ex-US rights to a differentiated proximal C3 mechanism that addresses the C5 suboptimal-responder population — directly attacking Alexion-AstraZeneca's European PNH revenues.